Refine by
Emergency Patient Articles & Analysis
59 news found
At best, most of us tolerate needles. Whether a vaccine, an IV drip, or a blood draw, we can talk ourselves through it with the knowledge that it is for the greater good and will only cause temporary discomfort. On the other side of the spectrum, there are people with such an intense fear of needles that they are considered to have a phobia, trypanophobia to be precise. Many articles have been ...
“This designation allows us to broaden our reach and provide innovative solutions to more healthcare professionals treating patients diagnosed with PE – on an increasingly global scale.” An estimated 435,000 PE events occur each year in the six largest European Union (EU) countries.1 Compared to the United States, the prevalence of PE is higher for those ...
Since the IDMC authorization, three patients have been dosed in the Phase 2 expansion cohort. This progress highlights the potential for gene therapy to go beyond rare diseases and to address larger patient populations with significant unmet needs, such as chronic cardiovascular diseases. ...
Over three years, individuals prescribed Zio XT were more likely than unmonitored individuals to have outpatient visits — including to cardiologists — but less likely to require emergency department visits or hospitalization. In patient-level projections, the group prescribed Zio XT had slightly better total and quality-adjusted survival (11.91 vs. ...
Baliga BIOS-03: Real world clinical outcomes of patients with diffuse midline glioma in a longitudinal outcomes registry Timothy J. ...
ByxCures
Observed only mild and transient adverse events, with no use of emergency epinephrine Observed 98.4% patient compliance to date with novel OMIT therapeutic modality Safely started patients on dose 4, potentially reducing the time to reach maintenance by several weeks NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., ...
I look forward to working with this talented and passionate management team to accelerate the development of Immune-Onc's portfolio of products that may improve outcomes for cancer patients who currently have limited treatment options,” said Mr. ...
Current methods to diagnose sepsis take more than 24 hours after a patient enters the emergency ward – by which time, the patient may already be well on their way towards tissue damage, organ failure, and death. ...
“Achievement of this important milestone in the Phase 2 portion of the study is a testament to the clinical need in this patient population and I am eager to see the Phase 2 results as they emerge,” said Thomas Povsic, M.D., Ph.D., Professor of Medicine, Duke University School of Medicine and National Principal Investigator for the EXACT study. ...
Government to develop yet another one of the critically important emergency treatment products” said the company founder and CEO, Amir Genosar. ...
With this agreement, H.U.B will become the third clinical center in the world to implement NT's ground-breaking technology, enabling new therapeutic options for cancer patients. BNCT is an emerging, biologically-targeted form of radiotherapy that destroys tumor cells with minimal impact to surrounding healthy cells. ...
With this agreement, H.U.B will become the third clinical center in the world to implement NT's ground-breaking technology, enabling new therapeutic options for cancer patients. BNCT is an emerging, biologically-targeted form of radiotherapy that destroys tumor cells with minimal impact to surrounding healthy cells. ...
Notably, the data showed positive trends in total exercise duration and reductions in patient symptoms and ischemic burden. Although patient numbers are small, preliminary data suggest that response may be correlated to administered dose. ...
SNG001 was well tolerated in the SPRINTER trial with a favourable safety profile consistent with previous studies: · The proportion of patients with any treatment-emergent adverse events (TEAE) related to study treatment was 22.6% for SNG001 vs. 25.4% for placebo. · The proportion of patients with any serious TEAE was 12.6% for ...
The study, “Assessment of a cellular host response test to risk-stratify suspected COVID-19 patients in the Emergency Department setting,” demonstrated that the IntelliSep test has the potential to rapidly risk-stratify patients independent of pathogen, an important finding as risk stratification may improve resource allocation in ...
Hypersensitivity reactions, including anaphylaxis, may occur in patients who receive Axumin. Emergency resuscitation equipment and personnel should be immediately available. Axumin use contributes to a patient's overall long-term cumulative radiation exposure, which is associated with an increased risk of cancer. Safe handling practices should ...
Andrew Barofsky, President and CEO of RevMedx, Inc., stated, “CE Mark on our XGAUZE product now makes our entire portfolio available to emergency responders and surgeons in the European Union and around the world. ...
ByRevMedx
(Nasdaq:HYPR), creator of Swoop®, the first FDA-cleared portable magnetic resonance imaging (MRI) system™, is proud to announce that Queen’s University and Kingston Health Sciences Centre are deploying a Swoop system as part of their health services benefitting six communities located in the James Bay and Hudson Bay Area. Until now, patients needing routine or ...
By incorporating Aidoc’s AI platform, which includes seven FDA-cleared solutions for triage and notification of patients with acute medical conditions, Novant Health is taking proactive steps to improve patient outcomes and reduce emergency department (ED) length of stay amid resource constraints inflicted by the Omicron variant. ...
ByAidoc
The objectives of the Phase 2, randomized, double-blind, placebo-controlled clinical study were to evaluate the safety, tolerability, and efficacy of two doses of REL-1017 tablets, 25 mg once a day and 50 mg once a day, when given as an adjunctive treatment for MDD in patients with inadequate response to standard antidepressants. A total of 62 patients were ...